
Rain could lead to more mosquitoes in Minnesota, experts say
Could the number of mosquitoes still increase in Minnesota this summer?
Could the number of mosquitoes still increase in Minnesota this summer?
Could the number of mosquitoes still increase in Minnesota this summer?
As Minnesotans prepare for backyard barbeques, an uninvited guest is making a strong comeback: mosquitoes.
Experts say cooler weather and low river levels could be responsible for our slow start to the mosquito season.
"Right now, mosquitos are well below average this time of year. But they're starting to creep back up," said Alex Carlson, with the Metropolitan Mosquito Control District.
Carlson says this year was the first time in three years we did not see a significant emergence of spring mosquitoes in May and early June. Rainfall expected this week could lead to significant increase. Specifically, a common summer nuisance, "cattail mosquitoes."
"They are very aggressive. They love to feed on us, but fortunately they typically don't carry disease just annoying and cause big red welts," Carlson said.
In response, aerial and ground treatments will continue as MMCD jump back into their busy season.
"We're going to be very busy next couple of days trying to get helicopters and getting staff out to do our treatments now, so we can knock down the population before the 4th of July," Carlson said.
Avoiding bites isn't just what officials do, it starts before you leave your house.
Mosquito control experts say there are some easy steps you can follow:
Make sure not to skip bug spray. Avoid dusk and dawn, when mosquitoes are most active. Skip sweet scents.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept. The partnership will use Ethris' advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific's industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities. A workstation in a research lab stocked with laboratory products and services. Ethris' platform technologies have already shown promising results. Specifically, the company's lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability. The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment
Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another for a once-daily oral formulation. These were published in The Lancet. Both formulations will progress to Phase 3 for weight management, which is a move supported by completed clinical studies and positive feedback from regulatory authorities. The executive vice president for Development at Novo Nordisk, Martin Holst Lange, expressed satisfaction with the results and regulatory feedback and highlighted the company's commitment to addressing obesity and expanding treatment options. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Amycretin is a unimolecular, long-acting GLP-1 and amylin receptor agonist, which is designed to target appetite regulation. It is being developed for adults with overweight or obesity, and also as a potential treatment for adults with type 2 diabetes. While Amycretin is not yet approved in the US for weight loss, these positive early-phase results strongly support its continued investigation in larger and longer-term Phase 3 trials to further assess its efficacy and safety. Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development
Cybin Inc. (NYSEAMERICAN:CYBN) is one of the best Canadian stocks with huge upside potential. On June 3, Cybin announced that the US Patent and Trademark Office granted US Patent No. 12,318,477. The new patent supports Cybin's CYB004 deuterated N, N-dimethyltryptamine (DMT) program, which is currently in Phase 2 development for the treatment of generalized anxiety disorder/GAD. The patent is expected to provide exclusivity until 2040 and covers novel formulations of DMT and deuterated isotopologues specifically for intramuscular/IM injection, including CYB004. The CEO of Cybin, Doug Drysdale, emphasized that the CYB004 program aims to offer a short-duration and rapid-acting treatment for anxiety disorders through patient-friendly IM administration. Dosing for the Phase 2 study of CYB004 in GAD is presently underway, with the study expected to be completed in mid-2025. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. Cybin's intellectual property portfolio consists of 90+ granted patents and 230+ pending applications. Beyond CYB004, the company is also developing CYB003, which is a proprietary deuterated psilocin program and is in Phase 3 development for the adjunctive treatment of major depressive disorder. Cybin maintains a research pipeline of investigational, 5-HT-receptor focused compounds and operates in Canada, the US, the UK, the Netherlands, and Ireland. Cybin Inc. (NYSEAMERICAN:CYBN) is a clinical-stage biopharmaceutical company that develops psychedelic-based therapeutics for patients with mental health conditions. While we acknowledge the potential of CYBN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio